证券代码：301408 证券简称：华人健康 公告编号：2023-054 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 特别提示： 1、安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"） 拟通过支付现金方式购买自然人王祥安、浙江自贸区雪源项目投资合伙企业（有 限合伙）（以下合称"交易对方一"）合计持有的舟山里肯医药连锁有限公司（ 以下简称"舟山里肯"）60%的股权及购买嘉兴乾达创业投资合伙企业（有限合 伙）（以下简称"交易对方二"）持有的嘉兴市老百姓药品零售有限公司（以下 简称"嘉兴老百姓"、目标公司）70%的股权（以下合称"本次交易"或"本次 收购"）。 2、公司于2023年7月12日在巨潮资讯网（www.cninfo.com.cn）发布的《安 徽华人健康医药股份有限公司关于筹划重大资产重组的提示性公告》已对本次交 易涉及的有关风险因素及尚需履行的审批程序进行了详细说明，并分别于2023 年8月11日、9月8日、10月9日披露了《关于筹划重大资产重组的进展公告》（公 告编号：2023-041、2023-049、2 ...

Financial Performance - The company's revenue for Q3 2023 reached ¥947,326,153.41, representing a year-on-year increase of 14.45%[5] - Net profit attributable to shareholders for the same period was ¥29,774,685.31, up 13.98% compared to the previous year[5] - Total operating revenue for Q3 2023 reached CNY 2,678,296,897.28, an increase of 19.7% compared to CNY 2,237,347,415.94 in the same period last year[21] - Net profit for Q3 2023 was CNY 88,631,391.41, representing a 30.4% increase from CNY 68,015,667.06 in Q3 2022[22] - The company reported a comprehensive income total of CNY 90,766,176.96 for Q3 2023, compared to CNY 68,015,667.06 in Q3 2022, an increase of 33.5%[22] - Total revenue attributable to the parent company reached ¥90,152,084.58, an increase from ¥68,314,912.36 in the previous period, reflecting a significant growth[23] - Basic and diluted earnings per share increased to ¥0.2276 from ¥0.2009, indicating improved profitability[23] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥4,427,479,863.47, reflecting a significant increase of 71.86% from the end of the previous year[5] - The company's total assets increased to CNY 4,427,479,863.47, compared to CNY 2,576,184,947.30 in the previous year, reflecting a growth of 72.0%[20] - Non-current assets totaled CNY 1,688,797,476.37, up from CNY 876,050,770.71, marking a 92.7% increase year-over-year[20] - The total liabilities reached CNY 2,480,000,662.95, an increase of 52.3% from CNY 1,629,179,024.60 in the previous year[20] - The company's equity attributable to shareholders rose to CNY 1,916,882,841.14, a remarkable increase of 102.36% compared to the previous year[5] - The company's equity attributable to shareholders rose to CNY 1,916,882,841.14, compared to CNY 947,278,655.70, indicating a growth of 102.5%[20] Cash Flow - The company's cash flow from operating activities for the year-to-date was ¥307,255,936.08, showing a substantial increase of 62.34%[5] - Cash flow from operating activities generated a net amount of ¥307,255,936.08, up from ¥189,265,859.39 in the prior period, showcasing enhanced operational efficiency[23] - Cash inflow from investment activities totaled ¥860,879,748.37, compared to ¥238,557,245.36 in the previous year, indicating increased investment returns[24] - Net cash flow from financing activities was ¥864,642,389.82, a turnaround from a net outflow of -¥132,651,242.76 in the prior period, reflecting stronger capital management[24] - The company reported a net increase in cash and cash equivalents of ¥444,079,372.21, compared to ¥2,489,482.77 in the previous period, enhancing liquidity[24] - Total cash and cash equivalents at the end of the period stood at ¥592,623,124.05, up from ¥58,259,378.23, indicating a solid cash position[24] Investments and Expenses - Research and development expenses surged to ¥8,848,463.74, marking a 286.64% increase, driven by enhanced drug development and information technology initiatives[11] - Research and development expenses increased to CNY 8,848,463.74, significantly higher than CNY 2,288,563.49 in the same quarter last year, reflecting a growth of 286.5%[21] - The company has made significant investments in fixed assets, which increased by 232.19% to ¥180,126,227.83, primarily due to the acquisition of Shenhua Pharmaceutical[10] - The company’s long-term borrowings increased by 1153.45% to ¥237,580,335.28, mainly for the Eastern Industrial Base construction project and acquisition loans[11] Shareholder Information - Total number of common shareholders at the end of the reporting period is 20,623[13] - Major shareholder He Jiale holds 50.12% of shares, totaling 200,493,326 shares, with 50,500,000 shares pledged[13] - Alibaba Health Technology (China) Limited holds 7.51% of shares, totaling 30,049,373 shares[13] - The top 10 shareholders include He Jialun with 6.89% (27,572,335 shares) and Huatai Zijin Investment with 5.24% (20,948,896 shares)[13] - The total number of restricted shares at the end of the period is 200,493,326, with no new restrictions added[15] - The company has a lock-up period for executives, with 1,800 shares released after one year post-IPO[15] - The company is focused on maintaining shareholder stability and compliance with lock-up regulations[15] Market Strategy and Outlook - The company is focused on expanding its market presence and developing new products, although specific details were not disclosed in the report[17] - Future guidance and performance outlook were not explicitly detailed in the conference call, indicating a cautious approach to market conditions[17] - The company did not report any significant mergers or acquisitions during the quarter, focusing on organic growth strategies[25] - The third quarter report was not audited, which may affect the perception of financial reliability[25] - The company is expected to continue its focus on expanding its market presence and enhancing product offerings in the upcoming quarters[25]

证券代码：301408 证券简称：华人健康 公告编号：2023-052 安徽华人健康医药股份有限公司 关于收购马鞍山曼迪新大药房连锁有限公司 重组后新公司51%股权的进展公告 2023年10月19日，公司收到通知，新公司已办理完成股权转让工商变更登记 手续并取得了换发的《营业执照》。具体信息如下： 企业名称：马鞍山国胜曼迪新大药房连锁有限公司 统一社会信用代码：91340500MA8QDJ3P17 企业类型：其他有限责任公司 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 一、交易概述 安徽华人健康医药股份有限公司(以下简称"公司"或"华人健康")于 2023年4月10日召开第四届董事会第八次会议，审议通过了《关于全资子公司安 徽国胜大药房连锁有限公司收购马鞍山曼迪新大药房连锁有限公司重组后新公 司51%股权的议案》，公司全资子公司安徽国胜大药房连锁有限公司(以下简称 "安徽国胜")与交易对手方冯灯贵、雍自定、王旭、张文、张亮、艾勤、马鞍 山市弘鑫企业管理中心(有限合伙)、马鞍山市国大药房连锁有限公司(以下简称 "出售方")以及马鞍山曼迪新大药房连锁有限 ...

证券代码：301408 证券简称：华人健康 公告编号：2023-051 安徽华人健康医药股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、特别提示 本次交易对方与公司、公司控股股东、实际控制人不存在关联关系，不构成 关联交易。根据初步测算，本次交易预计可能构成《上市公司重大资产重组管理 办法》规定的重大资产重组，但不涉及公司发行股份，也不会导致公司控制权变 更。 三、本次重大资产重组进展情况 截至本公告披露日，相关事项进展情况披露如下： 针对本次交易，公司聘请了中介机构进场开展工作，目前公司及有关各方正 在积极推进本次交易的相关工作，交易方案仍需进一步论证和沟通协商，尚需履 行内外部相关决策、审批程序。公司将根据本次交易的进展情况，严格按照相关 法律法规的规定履行有关的决策审批程序和信息披露义务。 四、风险提示 1、本次签署的协议仅为意向协议，具体的交易方案及交易条款由交易各方 协商确定，以各方签署的正式协议为准。 2、本次交易尚处于筹划阶段，交易方案仍需进一步论证和协商，并且审计、 评估尚在进行中，并需按照相 ...

本次保荐代表人更换后，公司首次公开发行股票的持续督导保荐代表人为范 杰先生和孟超先生，法定持续督导期至2026年12月31日止。 公司董事会对刘鹭先生在公司持续督导期间所做出的贡献表示衷心感谢！ 安徽华人健康医药股份有限公司 关于更换保荐代表人的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 安徽华人健康医药股份有限公司（以下简称"公司"）于近日收到保荐机构 华泰联合证券有限责任公司（以下简称"华泰联合证券"）出具的《关于更换安 徽华人健康医药股份有限公司首次公开发行股票持续督导保荐代表人的函》，华 泰联合证券作为公司首次公开发行股票并在创业板上市的保荐机构，原委派范杰 先生、刘鹭先生担任公司首次公开发行股票项目的保荐代表人，现刘鹭先生因工 作变动，无法继续履行持续督导职责。为保证持续督导工作的有序进行，华泰联 合证券决定委派孟超先生（后附简历）接替刘鹭先生担任公司在持续督导期间的 保荐代表人，继续履行公司首次公开发行股票的持续督导职责。 证券代码：301408 证券简称：华人健康 公告编号：2023-050 特此公告。 安徽华人健康医药股份有限公司董 ...

证券代码:301408 证券简称:华人健康 安徽华人健康医药股份有限公司 投资者关系活动记录表 编号:2023-004 投资者关系活动类别 ☐特定对象调研 ☐分析师会议 ☐媒体采访 ☐业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 其他(2023年安徽辖区上市公司投资者网上集体接待日活动) 参与单位名称及人 员姓名 线上参与2023年安徽辖区上市公司投资者网上集体接待日活动的投资者 时间 2023年09月12日15:30-17:30 地点 全景网"投资者关系互动平台"(https://ir.p5w.net) 董事会秘书、财务总监 李梅女士 上市公司接待人员姓 名 证券事务代表 黄莲莲女士 | --- | |-------------------------------------------------------------------| | 公司于2023年09月12日(星期二)下午15:30-17:30在全景网"投资者 | | 关系互动平台"(https://ir.p5w.net)参加2023年安徽辖区上市公司投资 | | 者网上集体接待日活动。本次投资者网上集体接待日的主要问答情况如下: | 1、公 ...

安徽华人健康医药股份有限公司 关于筹划重大资产重组的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 证券代码：301408 证券简称：华人健康 公告编号：2023-049 截至本公告披露日，相关事项进展情况披露如下： 针对本次交易，公司聘请了中介机构进场开展工作，目前公司及有关各方正 在积极推进本次交易的相关工作，交易方案仍需进一步论证和沟通协商，尚需履 行内外部相关决策、审批程序。公司将根据本次交易的进展情况，严格按照相关 法律法规的规定履行有关的决策审批程序和信息披露义务。 四、风险提示 1、本次签署的协议仅为意向协议，具体的交易方案及交易条款由交易各方 协商确定，以各方签署的正式协议为准。 一、特别提示 1、安徽华人健康医药股份有限公司（以下简称"华人健康"或"公司"） 拟通过支付现金方式购买自然人王祥安、浙江自贸区雪源项目投资合伙企业（有 限合伙）（以下合称"交易对方一"）合计持有的舟山里肯医药连锁有限公司（ 以下简称"舟山里肯"）60%的股权及购买嘉兴乾达创业投资合伙企业（有限合 伙）（以下简称"交易对方二"）持有的嘉兴市老百姓药品零售有 ...

证券代码:301408 证券简称:华人健康 公告编号:2023-048 安徽华人健康医药股份有限公司 关于参加2023年安徽辖区上市公司投资者网上集体 接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整,没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示: 1、活动时间:2023 年 9 月 12 日(星期二)15:30-17:30 2、活动地点:"全景路演"网站(https://rs.p5w.net) 3、活动方式:网络远程方式 为进一步加强与投资者的互动交流,安徽华人健康医药股份有限公司(以下 简称"公司")将参加由安徽证监局、安徽省上市公司协会与深圳市全景网络有 限公司联合举办的"2023 年安徽辖区上市公司投资者网上集体接待日"活动,现 将相关事项公告如下: 一、活动的时间、地点 时间:2023 年 9 月 12 日(星期二)15:30-17:30 地点:"全景路演"网站(https://rs.p5w.net) 二、活动方式 本次活动将采用网络远程的方式举行,公司将在线就 2023 年半年度业绩、 公司治理、发展战略、经营状况和可持续发展等投资者关心的问题,与投资者进 行沟通 ...

证券代码：301408 证券简称：华人健康 安徽华人健康医药股份有限公司 投资者关系活动记录表 编号：2023-003 投资者关系活动类别 特定对象调研 ☐分析师会议 ☐媒体采访 业绩说明会 ☐新闻发布会 ☐路演活动 ☐现场参观 其他（电话会议） 中信证券 沈睦钧、张斌斌、陈竹 中信建投证券 刘岚 华泰证券 王殷杰 东北证券 周骐、文将儒、刘宇腾、郑浩然、赵朝旋、钱彦君 江海证券（自营） 罗萍 深圳景泰利丰投资 邹军辉 嘉实基金 岳鹏飞 参与单位名称及人 员姓名 中加基金 温燕 华鑫医药 胡博新 华金新股 张竞元 天弘基金 刘盟盟 瑞信 赵悦伦 混沌天成 戴亦舒 东方阿尔法基金 朱黎斌 华鑫医药 吴景欢 时间 2023年08月25日 10:00-11:00 地点 公司6楼会议室及电话会 董事长、总经理 何家乐先生 董事、副总经理 何家伦先生 上市公司接待人员姓 名 董事会秘书、财务总监 李梅女士 投资部经理 王军先生 证券事务代表 黄莲莲女士 一、公司上半年业务发展状况？ | --- | |----------------------------------------------------------| ...

Financial Performance - The company reported a revenue of 500 million CNY for the first half of 2023, representing a 15% increase compared to the same period last year[14]. - The net profit for the first half of 2023 was 80 million CNY, which is a 10% increase year-over-year[14]. - The company's total revenue for the reporting period reached RMB 1,730,970,743.87, representing a 22.80% increase compared to RMB 1,409,626,450.37 in the same period last year[22]. - Net profit attributable to shareholders of the listed company was RMB 58,242,613.72, up 38.04% from RMB 42,192,370.18 year-on-year[22]. - The net cash flow from operating activities increased by 132.12% to RMB 207,523,054.20, compared to RMB 89,405,134.89 in the previous year[23]. - The company's total revenue for the first half of 2023 reached 2,702 million CNY[123]. - The company reported a total comprehensive income of CNY 60,137,354.29 for the first half of 2023, compared to CNY 42,085,136.57 in the previous year, indicating an increase of 42.93%[186]. - The company reported a net profit of 192 million yuan, which is a significant decline from the previous year's figures[197]. Market Expansion and Strategy - The company plans to expand its market presence by entering three new provinces in the second half of 2023[14]. - The company is actively expanding its market presence beyond Anhui province, with a strategic focus on building a comprehensive marketing network[42]. - The company plans to expand its retail business beyond Anhui province, focusing on economically developed neighboring provinces with high population density[91]. - The company is focused on optimizing and upgrading its business network layout through the acquisition of equity, enhancing its brand image[81]. - The company plans to explore potential mergers and acquisitions to strengthen its market position[121]. - The company is exploring potential mergers and acquisitions to enhance its product offerings and market reach[14]. Research and Development - Research and development expenses increased by 20% to 50 million CNY, focusing on new product development and technology enhancements[14]. - The company is focusing on the research and development of 22 drugs, including traditional Chinese medicine and generic drugs, through its subsidiary[49]. - Research and development investment surged by 729.43% to ¥4,329,232.28, reflecting the company's focus on enhancing drug development and information technology[60]. - The company is investing in research and development for new product lines to meet evolving consumer demands[121]. - Research and development expenses for the period were 2.1 million, representing an increase of 5.0% year-over-year[194]. Operational Efficiency and Digital Transformation - The company is implementing a new CRM system to improve customer engagement and service efficiency[14]. - The company has established centralized warehouses in Hefei and Bozhou, enhancing logistics efficiency and inventory management[54]. - The company has implemented a digital transformation strategy, including the development of a self-service POS system and B2B e-commerce platform[51]. - The company is focusing on digital transformation and product development through its technology reserves, aiming to become a retail ecosystem and technology-driven enterprise[41]. - The company is committed to improving operational efficiency to mitigate the effects of the current market challenges[198]. Financial Position and Investments - The company's registered capital increased from RMB 34,000,000 to RMB 40,001,000, and the total number of shares rose from 34 million to 40.001 million[21]. - The company's cash and cash equivalents increased significantly to ¥622,116,263.27, a dramatic rise of 10,075.84% attributed to funds raised from the company's IPO[60]. - The total investment amount for the reporting period reached ¥788,930,626.11, a significant increase of 245.56% compared to ¥228,306,704.53 in the same period last year[72]. - The company raised a total of RMB 974.56 million through its initial public offering, with a net amount of RMB 879.45 million after deducting various issuance costs[82]. - The company has a total of 108 party members as of the end of the reporting period[109]. Social Responsibility and Community Engagement - The company has engaged in social responsibility initiatives, contributing over 110,000 yuan in donations during community support activities[107]. - The company continues to prioritize public welfare as a key component of its development strategy[109]. - The company is committed to enhancing consumer protection and promoting a safe consumption environment through various initiatives[107]. Risks and Challenges - The management highlighted risks related to regulatory changes and market competition, with strategies in place to mitigate these risks[14]. - The company recognizes the risks of talent dilution due to rapid growth and is implementing measures to mitigate this risk[94]. - The company has not identified any major changes in its operational strategy or significant risks during this reporting period[81].